

Give atopic dogs the liquid cyclosporine they deserve with CYCLAVANCE™ oral solution

KEY FEATURE #1:

Reliability

ITS BENEFIT:

- Cyclosporine is recommended by ICADA for the treatment of AD in dogs¹
 - Blocks the release of inflammatory cytokines
 - Exhibits strong anti-inflammatory and anti-pruritic effects
- Maintains long-term beneficial effects with 1 dose every other day or twice weekly²

KEY FEATURE #2:

Precision in dosing

ITS BENEFIT:

- Liquid formulation allows for precise dosing at 5 mg/kg for all dogs
- When compared with CYCLAVANCE oral solution at 5 mg/kg, variance in dosing for cyclosporine capsules can range from -29% to +33%^{2,3}

KEY FEATURE #3:

Confidence in delivery

ITS BENEFIT:

- Convenient and easy dosing to help promote compliance
- In an acceptance study, 99.3% of dogs accepted the entire dose of CYCLAVANCE oral solution when deposited in their mouths
- 98.3% consumed the whole dose when mixed with a small amount of food⁴

IMPORTANT SAFETY INFORMATION

CYCLAVANCE (cyclosporine oral solution) USP Modified: For use in dogs only. Wear gloves during and wash hands after administration. Gastrointestinal problems and gingival hyperplasia may occur at the initial recommended dose of CYCLAVANCE Oral Solution for Dogs. CYCLAVANCE Oral Solution for Dogs should be used with caution: 1) in cases with diabetes mellitus as it may cause elevated levels of serum glucose; 2) in dogs with renal insufficiency since the effect of cyclosporine use on dogs with compromised renal function has not been studied; 3) in simultaneous administration with drugs that suppress the P-450 enzyme system, such as azoles (e.g. ketoconazole), that may lead to increased plasma levels of cyclosporine. Killed vaccines are recommended for dogs receiving CYCLAVANCE Oral Solution for Dogs because the impact of cyclosporine on the immune response to modified live vaccines has not been evaluated. For full prescribing information, contact Virbac at 1-800-338-3659 or visit us.virbac.com.

References: 1. Olivry T, DeBoer DJ, Favrot C, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). *BMC Vet Res.* 2015;11:1-15. 2. CYCLAVANCE™ (cyclosporine oral solution) USP MODIFIED [product label]. Fort Worth, TX: Virbac AH, Inc.; 2020. 3. ATOPICA™ (cyclosporine capsules) [product label]. Greenfield, IN: Elanco US Inc.; 2020. 4. Navarro C, Crastes N, Benizeau E, McGahie D. Voluntary acceptance and consumption of two oral ciclosporin formulations in dogs: two randomised, controlled studies. *Ir Vet J.* 2015;68:1-8. 5. Data on file. Virbac Corporation.

© 2021 Virbac Corporation. All Rights Reserved. CYCLAVANCE is a registered trademark of Virbac S.A.

**sound
byte**



<https://vet-us.virbac.com/cyclavance>
1-844-484-7222




Cyclavance™

(cyclosporine oral solution)
USP MODIFIED

Mean cyclosporine plasma concentration (ng/mL) following administration at 5 mg/kg of CYCLAVANCE oral solution and cyclosporine capsules⁵



Cyclosporine capsules variance from 5 mg/kg ideal dose^{2,3*}



*Based on dosing recommendations in cyclosporine capsules package insert.²

References: 1. Olivry T, DeBoer DJ, Favrot C, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). *BMC Vet Res.* 2015;11:1–15. 2. CYCLAVANCE™ (cyclosporine oral solution) USP MODIFIED [product label]. Fort Worth, TX: Virbac AH, Inc.; 2020. 3. ATOPICA™ (cyclosporine capsules) [product label]. Greenfield, IN: Elanco US Inc.; 2020. 4. Navarro C, Crastes N, Benizeau E, McGahie D. Voluntary acceptance and consumption of two oral cyclosporin formulations in dogs: two randomised, controlled studies. *Ir Vet J.* 2015;68:1–8. 5. Data on file. Virbac Corporation.

sound CHECK-OFF & ECHO NOTES byte

First, always ask if a Virbac representative has been in contact recently:

Doctor, have you recently been introduced to CYCLAVANCE™ (cyclosporine oral solution) USP MODIFIED?

If **YES**, confirm and discuss benefits.

If **NO**, engage/detail the customer as the primary contact.

Confidence

I believe CYCLAVANCE oral solution will provide an important tool for managing canine atopic dermatitis in your patients.

Neutral invitation

Let's take a look at some basic information about CYCLAVANCE oral solution...

It's the customer's decision

...so you can decide whether CYCLAVANCE oral solution is a solution you'll consider for your patients presenting with signs of atopic dermatitis.